Late Primary Graft Dysfunction After Lung Transplantation and Bronchiolitis Obliterans Syndrome

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2008 Sep 13

PMID 18785961

Citations 50

Authors

H J Huang

R D Yusen

B F Meyers

M J Walter

T Mohanakumar

G A Patterson

E P Trulock

R R Hachem

Affiliations

Soon will be listed here.

Abstract

Primary graft dysfunction (PGD) is a common early complication after lung transplantation. We conducted a retrospective cohort study of 334 recipients to evaluate the impact of PGD graded at 24, 48 and 72 h on the risk of bronchiolitis obliterans syndrome (BOS) development (stage 1) and progression (stages 2 and 3). We constructed multivariable Cox proportional hazards models to determine the risk of BOS attributable to PGD in the context of other potential risk factors including acute rejection, lymphocytic bronchitis and respiratory viral infections. All grades of PGD at all time points were significant risk factors for BOS development and progression independent of acute rejection, lymphocytic bronchitis and respiratory viral infections. Specifically, PGD grade 1 at T24 was associated with a relative risk of BOS stage 1 of 1.93, grade 2 with a relative risk of 2.29 and grade 3 with a relative risk of 3.31. Furthermore, this direct relationship between the severity of PGD and the risk of BOS persisted at all time points. We conclude that all grades of PGD at all time points are independent risk factors for BOS development and progression. Future strategies that might attenuate the severity of PGD may mitigate the risk of BOS.

Citing Articles

Differentially expressed microRNAs in pre-transplant lung biopsies target immune checkpoint proteins and can predict primary graft dysfunction in lung transplantation.

Miceli V, Ferrigno P, Centi C, Carcione C, Iannolo G, Agnese V Heliyon. 2025; 11(4):e42515.

PMID: 40028527 PMC: 11869042. DOI: 10.1016/j.heliyon.2025.e42515.

Predicting Primary Graft Dysfunction in Lung Transplantation: Machine Learning-Guided Biomarker Discovery.

Nord D, Brunson J, Langerude L, Moussa H, Gill B, Machuca T bioRxiv. 2024; .

PMID: 39386627 PMC: 11463600. DOI: 10.1101/2024.05.24.595368.

Contrasting predictors of severe primary graft dysfunction following transplant for chronic and acute respiratory failure.

Kurihara C, Kaiho T, Thomae B, Cerier E, Lung K, Avella Patino D J Thorac Dis. 2024; 16(8):5050-5062.

PMID: 39268121 PMC: 11388248. DOI: 10.21037/jtd-24-100.

Donor Fractions of Cell-Free DNA Are Elevated During CLAD But Not During Infectious Complications After Lung Transplantation.

Novo M, Norden R, Westin J, Dellgren G, Bohmer J, Ricksten A Transpl Int. 2024; 37:12772.

PMID: 39114640 PMC: 11303165. DOI: 10.3389/ti.2024.12772.

Is logistically motivated lung perfusion a good idea?.

Van De Wauwer C, van Suylen V, Zhang Z, Verschuuren E, van der Bij W, Gan C Front Transplant. 2024; 1:988950.

PMID: 38994392 PMC: 11235284. DOI: 10.3389/frtra.2022.988950.

References

Waddell T, Gorczynski R, DeCampos K, Patterson G, Slutsky A . Major histocompatibility complex expression and lung ischemia-reperfusion in rats. Ann Thorac Surg. 1996; 62(3):866-72. DOI: 10.1016/s0003-4975(96)00509-7. View

Nicod L . Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc. 2006; 3(5):444-9. DOI: 10.1513/pats.200601-007AW. View

Daud S, Yusen R, Meyers B, Chakinala M, Walter M, Aloush A . Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006; 175(5):507-13. DOI: 10.1164/rccm.200608-1079OC. View

Bharat A, Fields R, Steward N, Trulock E, Patterson G, Mohanakumar T . CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant. 2006; 6(8):1799-808. DOI: 10.1111/j.1600-6143.2006.01383.x. View

Goers T, Ramachandran S, Aloush A, Trulock E, Patterson G, Mohanakumar T . De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008; 180(7):4487-94. PMC: 2796833. DOI: 10.4049/jimmunol.180.7.4487. View

Estenne M, Maurer J, Boehler A, Egan J, Frost A, Hertz M . Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002; 21(3):297-310. DOI: 10.1016/s1053-2498(02)00398-4. View

Whitson B, Nath D, Johnson A, Walker A, Prekker M, Radosevich D . Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006; 131(1):73-80. DOI: 10.1016/j.jtcvs.2005.08.039. View

Cooper J, Billingham M, Egan T, Hertz M, Higenbottam T, Lynch J . A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993; 12(5):713-6. View

Khalifah A, Hachem R, Chakinala M, Schechtman K, Patterson G, Schuster D . Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004; 170(2):181-7. DOI: 10.1164/rccm.200310-1359OC. View

10.

Yousem S, Berry G, Cagle P, Chamberlain D, Husain A, Hruban R . Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1996; 15(1 Pt 1):1-15. View

11.

van Kuppevelt T, Veerkamp J, Timmermans J . Immunoquantification of type I, III, IV and V collagen in small samples of human lung parenchyma. Int J Biochem Cell Biol. 1995; 27(8):775-82. DOI: 10.1016/1357-2725(95)00047-s. View

12.

Christie J, Kotloff R, Ahya V, Tino G, Pochettino A, Gaughan C . The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005; 171(11):1312-6. PMC: 2718464. DOI: 10.1164/rccm.200409-1243OC. View

13.

Christie J, Van Raemdonck D, de Perrot M, Barr M, Keshavjee S, Arcasoy S . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant. 2005; 24(10):1451-3. DOI: 10.1016/j.healun.2005.03.004. View

14.

Burton C, Iversen M, Milman N, Zemtsovski M, Carlsen J, Steinbruchel D . Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg. 2006; 31(1):75-82. DOI: 10.1016/j.ejcts.2006.10.024. View

15.

Bharat A, Fields R, Trulock E, Patterson G, Mohanakumar T . Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol. 2006; 177(8):5631-8. DOI: 10.4049/jimmunol.177.8.5631. View

16.

Bharat A, Narayanan K, Street T, Fields R, Steward N, Aloush A . Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation. 2007; 83(2):150-8. DOI: 10.1097/01.tp.0000250579.08042.b6. View

17.

Haque M, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz R, Zheng Y . Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol. 2002; 169(3):1542-9. DOI: 10.4049/jimmunol.169.3.1542. View

18.

Magro C, Ross Jr P, Kelsey M, Waldman W, Pope-Harman A . Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant. 2003; 3(9):1155-66. DOI: 10.1034/j.1600-6143.2003.00168.x. View

19.

Girnita A, Duquesnoy R, Yousem S, Iacono A, Corcoran T, Buzoianu M . HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant. 2005; 5(1):131-8. DOI: 10.1111/j.1600-6143.2004.00650.x. View

20.

Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb T . Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant. 2006; 6(4):724-35. DOI: 10.1111/j.1600-6143.2006.01236.x. View